Found: 62
Select item for more details and to access through your institution.
Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 2, p. 227, doi. 10.1007/s10637-017-0436-1
- By:
- Publication type:
- Article
Changes in Serum Erythropoietin Levels during Chemotherapy for Lung Cancer.
- Published in:
- Chemotherapy (0009-3157), 1992, v. 38, n. 5, p. 281, doi. 10.1159/000239014
- By:
- Publication type:
- Article
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).
- Published in:
- Oncology & Therapy, 2022, v. 10, n. 1, p. 253, doi. 10.1007/s40487-022-00188-2
- By:
- Publication type:
- Article
Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.685320
- By:
- Publication type:
- Article
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.
- Published in:
- PLoS ONE, 2021, v. 16, n. 11, p. 1, doi. 10.1371/journal.pone.0260500
- By:
- Publication type:
- Article
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
- Published in:
- International Journal of Oncology, 2020, v. 56, n. 6, p. 1479, doi. 10.3892/ijo.2020.5019
- By:
- Publication type:
- Article
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
- Published in:
- International Journal of Oncology, 2015, v. 46, n. 1, p. 55, doi. 10.3892/ijo.2014.2699
- By:
- Publication type:
- Article
Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome.
- Published in:
- Cancer Reports, 2024, v. 7, n. 7, p. 1, doi. 10.1002/cnr2.2145
- By:
- Publication type:
- Article
Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases.
- Published in:
- Cancer Reports, 2024, v. 7, n. 2, p. 1, doi. 10.1002/cnr2.1981
- By:
- Publication type:
- Article
Single nucleotide polymorphisms of the haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination.
- Published in:
- Oncology Letters, 2017, v. 13, n. 2, p. 993, doi. 10.3892/ol.2016.5467
- By:
- Publication type:
- Article
Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L).
- Published in:
- Cancer Management & Research, 2021, v. 13, p. 9167, doi. 10.2147/CMAR.S336262
- By:
- Publication type:
- Article
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1354, doi. 10.1007/s10147-023-02390-2
- By:
- Publication type:
- Article
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 1, p. 79, doi. 10.1007/s10147-022-02266-x
- By:
- Publication type:
- Article
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
- Published in:
- International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1828, doi. 10.1007/s10147-022-02232-7
- By:
- Publication type:
- Article
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 3, p. 515, doi. 10.1007/s10147-020-01828-1
- By:
- Publication type:
- Article
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
- Published in:
- International Journal of Clinical Oncology, 2019, v. 24, n. 5, p. 485, doi. 10.1007/s10147-019-01396-z
- By:
- Publication type:
- Article
Observational study of chemotherapy-induced Clostridium difficile infection in patients with lung cancer.
- Published in:
- International Journal of Clinical Oncology, 2018, v. 23, n. 6, p. 1046, doi. 10.1007/s10147-018-1304-5
- By:
- Publication type:
- Article
Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.
- Published in:
- International Journal of Clinical Oncology, 2009, v. 14, n. 1, p. 43, doi. 10.1007/s10147-008-0796-9
- By:
- Publication type:
- Article
Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. e410, doi. 10.1093/oncolo/oyac056
- By:
- Publication type:
- Article
Phase II Study of Low‐Dose Afatinib Maintenance Treatment Among Patients with EGFR‐Mutated Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
- Published in:
- Oncologist, 2020, v. 25, n. 10, p. e1451, doi. 10.1634/theoncologist.2020-0545
- By:
- Publication type:
- Article
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti‐Programmed Cell Death 1 Monotherapy for Advanced Non‐Small Cell Lung Cancer.
- Published in:
- Oncologist, 2020, v. 25, n. 3, p. e536, doi. 10.1634/theoncologist.2019-0550
- By:
- Publication type:
- Article
Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab.
- Published in:
- Oncologist, 2018, v. 23, n. 11, p. 1358, doi. 10.1634/theoncologist.2017-0384
- By:
- Publication type:
- Article
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
- Published in:
- Oncologist, 2017, v. 22, n. 6, p. 640, doi. 10.1634/theoncologist.2017-0059
- By:
- Publication type:
- Article
Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel and Docetaxel Alone in Elderly Patients With Advanced Non-Small Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 352, doi. 10.1634/theoncologist.2013-0411
- By:
- Publication type:
- Article
A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
- Published in:
- Oncologist, 2013, v. 18, n. 4, p. 439, doi. 10.1634/theoncologist.2012-0308
- By:
- Publication type:
- Article
Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial.
- Published in:
- Oncologist, 2012, v. 17, n. 6, p. 863, doi. 10.1634/theoncologist.2011-0426
- By:
- Publication type:
- Article
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
- Published in:
- 2019
- By:
- Publication type:
- journal article
Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 2, p. 718, doi. 10.1002/cam4.3639
- By:
- Publication type:
- Article
Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge.
- Published in:
- Thoracic Cancer, 2023, v. 14, n. 31, p. 3140, doi. 10.1111/1759-7714.15107
- By:
- Publication type:
- Article
Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.
- Published in:
- Thoracic Cancer, 2023, v. 14, n. 27, p. 2804, doi. 10.1111/1759-7714.15076
- By:
- Publication type:
- Article
EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0078389
- By:
- Publication type:
- Article
Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 16, p. 17061, doi. 10.1002/cam4.6348
- By:
- Publication type:
- Article
Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01).
- Published in:
- Cancer Medicine, 2023, v. 12, n. 8, p. 9133, doi. 10.1002/cam4.5652
- By:
- Publication type:
- Article
Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804).
- Published in:
- 2022
- By:
- Publication type:
- journal article
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 7, p. 1177, doi. 10.1007/s00262-020-02536-5
- By:
- Publication type:
- Article
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
- Published in:
- Japanese Journal of Clinical Oncology, 2019, v. 49, n. 1, p. 29, doi. 10.1093/jjco/hyy179
- By:
- Publication type:
- Article
Treatments and outcomes of advanced/ recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan.
- Published in:
- Japanese Journal of Clinical Oncology, 2016, v. 46, n. 12, p. 1135, doi. 10.1093/jjco/hyw124
- By:
- Publication type:
- Article
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
- Published in:
- Japanese Journal of Clinical Oncology, 2015, v. 45, n. 7, p. 670, doi. 10.1093/jjco/hyv054
- By:
- Publication type:
- Article
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.
- Published in:
- Cancers, 2023, v. 15, n. 17, p. 4231, doi. 10.3390/cancers15174231
- By:
- Publication type:
- Article